X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STERLING BIOTECH - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STERLING BIOTECH GLENMARK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 19.3 -0.4 - View Chart
P/BV x 3.4 0.0 23,702.8% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
STERLING BIOTECH
Dec-13
GLENMARK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs93011 8,857.1%   
Low Rs5173 15,217.6%   
Sales per share (Unadj.) Rs322.626.8 1,203.5%  
Earnings per share (Unadj.) Rs28.5-15.0 -190.5%  
Cash flow per share (Unadj.) Rs39.2-5.5 -717.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.054.9 333.4%  
Shares outstanding (eoy) m282.17267.87 105.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 865.2%   
Avg P/E ratio x25.4-0.5 -5,466.9%  
P/CF ratio (eoy) x18.5-1.3 -1,451.6%  
Price / Book Value ratio x4.00.1 3,123.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,862 10,968.8%   
No. of employees `00013.71.4 1,013.0%   
Total wages/salary Rs m18,718547 3,423.3%   
Avg. sales/employee Rs Th6,636.85,303.3 125.1%   
Avg. wages/employee Rs Th1,364.7403.8 337.9%   
Avg. net profit/employee Rs Th586.1-2,959.0 -19.8%   
INCOME DATA
Net Sales Rs m91,0317,181 1,267.7%  
Other income Rs m91443 2,145.5%   
Total revenues Rs m91,9457,223 1,272.9%   
Gross profit Rs m16,154947 1,706.0%  
Depreciation Rs m3,0192,543 118.7%   
Interest Rs m2,8564,377 65.2%   
Profit before tax Rs m11,193-5,931 -188.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-1,924 -163.9%   
Profit after tax Rs m8,039-4,007 -200.6%  
Gross profit margin %17.713.2 134.6%  
Effective tax rate %28.232.4 86.9%   
Net profit margin %8.8-55.8 -15.8%  
BALANCE SHEET DATA
Current assets Rs m69,88714,335 487.5%   
Current liabilities Rs m32,87949,809 66.0%   
Net working cap to sales %40.7-494.0 -8.2%  
Current ratio x2.10.3 738.6%  
Inventory Days Days81403 20.2%  
Debtors Days Days93171 54.8%  
Net fixed assets Rs m28,89255,432 52.1%   
Share capital Rs m282268 105.3%   
"Free" reserves Rs m51,35313,935 368.5%   
Net worth Rs m51,63514,701 351.2%   
Long term debt Rs m41,4189,478 437.0%   
Total assets Rs m125,95473,988 170.2%  
Interest coverage x4.9-0.4 -1,386.0%   
Debt to equity ratio x0.80.6 124.4%  
Sales to assets ratio x0.70.1 744.7%   
Return on assets %8.60.5 1,726.8%  
Return on equity %15.6-27.3 -57.1%  
Return on capital %15.1-6.4 -235.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m36,3171,860 1,952.7%   
Fx outflow Rs m9,72025 39,050.2%   
Net fx Rs m26,5981,835 1,449.5%   
CASH FLOW
From Operations Rs m16,4811,719 958.9%  
From Investments Rs m-10,133-3,148 321.9%  
From Financial Activity Rs m-4,6851,426 -328.5%  
Net Cashflow Rs m1,770-3 -52,058.8%  

Share Holding

Indian Promoters % 48.3 33.9 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 9.9 347.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   56,727 21,482 264.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  ABBOTT INDIA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 7, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SHASUN PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS